Tao Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tao Yu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Bo Chen
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
1 shared publicationHuo Liang
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
1 shared publicationJianing Xu
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publicationJiatong Liu
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publicationJing-Jing Sun
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
1 shared publicationLiang Huo
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication
Latest Publications
- Open Access
- 5 February 2026
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 23 (1)
Ketogenic diet can inhibit epileptic seizures by inhibiting RGMa methylation to promote GluA1 palmitoylation in the epileptic rat model
This study investigated the relationship between the ketogenic diet, RGMa methylation, and GluA1 palmitoylation in a rat model of epilepsy, aiming to ident
- 5 February 2026
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 23 (1)
Open AccessKetogenic diet can inhibit epileptic seizures by inhibiting RGMa methylation to promote GluA1 palmitoylation in the epileptic rat model
This study investigated the relationship between the ketogenic diet, RGMa methylation, and GluA1 palmitoylation in a rat model of epilepsy, aiming to ident
- 11 February 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (6) , 7738-7746
Serum Inflammatory Factors Levels and Risk of Myasthenia Gravis: A Bidirectional Mendelian Randomization Study
Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness, where the role of inflammatory processes remains incompletely understood. Bidirectional Mendelian randomization (MR) provides a method to explore potential causal relationships between traits. In this bidirectional MR study, we investigated the relationship between 40 serum inflammatory factors and MG using the two-sample MR approach. The inverse variance weighted (IVW) method was the primary analytical method. Factors with P < 0.05 after false discovery rate (FDR) correction were considered to have a significant causal relationship with MG. Bayesian colocalization and functional mapping were employed to further analyze the instrumental variables. We then used reverse MR to examine potential reverse causality and validated these findings in the UK Biobank-PPP cohort. A phenome-wide association study (PheWAS) was conducted using UK Biobank and FinnGen data to evaluate the potential side effects of targeting these inflammatory factors as therapeutic interventions. Our results indicated that elevated levels of serum interleukin-10 (IL-10) were associated with a decreased risk of MG (P = 9.34E-03, OR [95% CI] = 0.52 [0.33–0.85]). Reverse MR revealed no evidence of reverse causality (P > 0.05), with further validation in the UK Biobank-PPP cohort (P = 3.81E-3, OR [95% CI] = 5.43E-02 [7.54E-03–3.91E-01]). The PheWAS outcomes showed associations of serum IL-10 levels across a broad phenotypic spectrum. Our findings suggest that IL-10 may play a protective role in the pathogenesis of MG. The absence of reverse causality highlights IL-10 as a potential therapeutic target. This study emphasizes the importance of inflammatory factors in autoimmune disorders and supports the utility of MR studies in uncovering novel therapeutic targets.
- 11 February 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (6) , 7738-7746
Serum Inflammatory Factors Levels and Risk of Myasthenia Gravis: A Bidirectional Mendelian Randomization Study
Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness, where the role of inflammatory processes remains incompletely understood. Bidirectional Mendelian randomization (MR) provides a method to explore potential causal relationships between traits. In this bidirectional MR study, we investigated the relationship between 40 serum inflammatory factors and MG using the two-sample MR approach. The inverse variance weighted (IVW) method was the primary analytical method. Factors with P < 0.05 after false discovery rate (FDR) correction were considered to have a significant causal relationship with MG. Bayesian colocalization and functional mapping were employed to further analyze the instrumental variables. We then used reverse MR to examine potential reverse causality and validated these findings in the UK Biobank-PPP cohort. A phenome-wide association study (PheWAS) was conducted using UK Biobank and FinnGen data to evaluate the potential side effects of targeting these inflammatory factors as therapeutic interventions. Our results indicated that elevated levels of serum interleukin-10 (IL-10) were associated with a decreased risk of MG (P = 9.34E-03, OR [95% CI] = 0.52 [0.33–0.85]). Reverse MR revealed no evidence of reverse causality (P > 0.05), with further validation in the UK Biobank-PPP cohort (P = 3.81E-3, OR [95% CI] = 5.43E-02 [7.54E-03–3.91E-01]). The PheWAS outcomes showed associations of serum IL-10 levels across a broad phenotypic spectrum. Our findings suggest that IL-10 may play a protective role in the pathogenesis of MG. The absence of reverse causality highlights IL-10 as a potential therapeutic target. This study emphasizes the importance of inflammatory factors in autoimmune disorders and supports the utility of MR studies in uncovering novel therapeutic targets.
- Open Access
- 17 November 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 1025813
Construction of an immune-related ceRNA network to screen for potential diagnostic markers for autism spectrum disorder
Purpose: The diagnosis of autism spectrum disorder (ASD) is reliant on evaluation of patients’ behavior. We screened the potential diagnostic and therapeutic targets of ASD through bioinformatics analysis.Methods: Four ASD-related datasets were downloaded from the Gene Expression Omnibus database. The “limma” package was employed to analyze differentially expressed messenger (m)RNAs, long non-coding (lnc)RNAs, and micro (mi)RNAs between ASD patients and healthy volunteers (HVs). We constructed a competing endogenous-RNA (ceRNA) network. Enrichment analyses of key genes were undertaken using the Gene Ontology database and Kyoto Encyclopedia of Genes and Genomes database. The ImmucellAI database was used to analyze differences in immune-cell infiltration (ICI) in ASD and HV samples. Synthetic analyses of the ceRNA network and ICI was done to obtain a diagnostic model using LASSO regression analysis. Analyses of receiver operating characteristic (ROC) curves were done for model verification.Results: The ceRNA network comprised 49 lncRNAs, 30 miRNAs, and 236 mRNAs. mRNAs were associated with 41 cellular components, 208 biological processes, 39 molecular functions, and 35 regulatory signaling pathways. Significant differences in the abundance of 10 immune-cell species between ASD patients and HVs were noted. Using the ceRNA network and ICI results, we constructed a diagnostic model comprising five immune cell-associated genes: adenosine triphosphate-binding cassette transporter A1 (ABCA1), DiGeorge syndrome critical region 2 (DGCR2), glucose-fructose oxidoreductase structural domain gene 1 (GFOD1), glutaredoxin (GLRX), and SEC16 homolog A (SEC16A). The diagnostic performance of our model was revealed by an area under the ROC curve of 0.923. Model verification was done using the validation dataset and serum samples of patients.Conclusion:ABCA1, DGCR2, GFOD1, GLRX, and SEC16A could be diagnostic biomarkers and therapeutic targets for ASD.
- 17 November 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 1025813
Open AccessConstruction of an immune-related ceRNA network to screen for potential diagnostic markers for autism spectrum disorder
Purpose: The diagnosis of autism spectrum disorder (ASD) is reliant on evaluation of patients’ behavior. We screened the potential diagnostic and therapeutic targets of ASD through bioinformatics analysis.Methods: Four ASD-related datasets were downloaded from the Gene Expression Omnibus database. The “limma” package was employed to analyze differentially expressed messenger (m)RNAs, long non-coding (lnc)RNAs, and micro (mi)RNAs between ASD patients and healthy volunteers (HVs). We constructed a competing endogenous-RNA (ceRNA) network. Enrichment analyses of key genes were undertaken using the Gene Ontology database and Kyoto Encyclopedia of Genes and Genomes database. The ImmucellAI database was used to analyze differences in immune-cell infiltration (ICI) in ASD and HV samples. Synthetic analyses of the ceRNA network and ICI was done to obtain a diagnostic model using LASSO regression analysis. Analyses of receiver operating characteristic (ROC) curves were done for model verification.Results: The ceRNA network comprised 49 lncRNAs, 30 miRNAs, and 236 mRNAs. mRNAs were associated with 41 cellular components, 208 biological processes, 39 molecular functions, and 35 regulatory signaling pathways. Significant differences in the abundance of 10 immune-cell species between ASD patients and HVs were noted. Using the ceRNA network and ICI results, we constructed a diagnostic model comprising five immune cell-associated genes: adenosine triphosphate-binding cassette transporter A1 (ABCA1), DiGeorge syndrome critical region 2 (DGCR2), glucose-fructose oxidoreductase structural domain gene 1 (GFOD1), glutaredoxin (GLRX), and SEC16 homolog A (SEC16A). The diagnostic performance of our model was revealed by an area under the ROC curve of 0.923. Model verification was done using the validation dataset and serum samples of patients.Conclusion:ABCA1, DGCR2, GFOD1, GLRX, and SEC16A could be diagnostic biomarkers and therapeutic targets for ASD.